370 related articles for article (PubMed ID: 26602841)
1. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
[TBL] [Abstract][Full Text] [Related]
2. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
4. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
[TBL] [Abstract][Full Text] [Related]
5. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
6. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
7. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
Ridwelski K; Meyer F; Schmidt U; Lippert H
Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Cancer Surgery: The New R-status Counts.
Strobel O; Hank T; Hinz U; Bergmann F; Schneider L; Springfeld C; Jäger D; Schirmacher P; Hackert T; Büchler MW
Ann Surg; 2017 Mar; 265(3):565-573. PubMed ID: 27918310
[TBL] [Abstract][Full Text] [Related]
9. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
10. Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors.
Mitra A; Pai E; Dusane R; Ranganathan P; DeSouza A; Goel M; Shrikhande SV
Langenbecks Arch Surg; 2018 Mar; 403(2):203-212. PubMed ID: 29362882
[TBL] [Abstract][Full Text] [Related]
11. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
12. Well or poorly differentiated nonfunctioning neuroendocrine carcinoma of the pancreas: a single institution experience with 17 cases.
Sellner F; Sobhian B; De Santis M; Pont J; Staettner S; Sellner S; Karner J; Klimpfinger M
Eur J Surg Oncol; 2008 Feb; 34(2):191-5. PubMed ID: 17475440
[TBL] [Abstract][Full Text] [Related]
13. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
[TBL] [Abstract][Full Text] [Related]
14. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
15. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
17. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.
Basturk O; Tang L; Hruban RH; Adsay V; Yang Z; Krasinskas AM; Vakiani E; La Rosa S; Jang KT; Frankel WL; Liu X; Zhang L; Giordano TJ; Bellizzi AM; Chen JH; Shi C; Allen P; Reidy DL; Wolfgang CL; Saka B; Rezaee N; Deshpande V; Klimstra DS
Am J Surg Pathol; 2014 Apr; 38(4):437-47. PubMed ID: 24503751
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
19. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract][Full Text] [Related]
20. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
